FDBusiness.com

AB-Biotics seeks partners at Vitafoods Europe to market its cholesterol-lowering and IBS probiotics

 Breaking News
  • British Brewers Decrease Their CO2 Emissions by 42% Total CO2 emissions from the UK’s brewing industry have fallen by 42% in the last decade (2008 to 2018) – a reduction of 202,952 tonnes – according to new research conducted by the British Beer & Pub Association (BBPA). The research also found that the energy used to brew a pint of beer in the [...]...
  • Small Irish Snack Manufacturer Secures Major Contract With Tesco Pinkfinch, a County Down-based fruit snacks supplier, has secured a major contract with Tesco Ireland, which will see an estimated 100,000 bags sold annually. From launching his business in his parent’s spare bedroom five years ago,  Pinkfinch founder Michael Heaslip (pictured) has grown his innovative product line across Ireland, the UK, Europe, and the Middle East,  with [...]...
  • UK Supermarkets are Struggling to Grow The latest grocery market share figures, published by Kantar, show year-on-year supermarket sales were flat during the 12 weeks to 11 August 2019 as the tough comparisons with 2018’s strong summer continue. The memory of last year still looms large for retailers and this summer’s comparatively poor weather, combined with low levels of like-for-like price [...]...
  • Tickets Still Available For 2019 Irish Food & Drink Business Awards Some tickets are still available for the 2019 Irish Food & Drink Business Awards presentation ceremony and gala dinner to be held at the Citywest Hotel in Dublin on the evening of Thursday, 5 September 2019. The winners of the 2019 Awards will be named at the event. The prestigious awards programme, which was first introduced [...]...
  • Nestlé UK Launches New On-trend Flavours Nestlé has introduced two new on-trend flavours to its much-loved Munchies brand in the UK and Ireland. Available in 101g sharing bags, new Munchies Chocolate Fudge Brownie and Munchies Cookie Dough are the first new Munchies products since 1996. The new flavours were created at Nestlé’s confectionery sites in York and Fawdon, Newcastle. Munchies Brand Manager [...]...

AB-Biotics seeks partners at Vitafoods Europe to market its cholesterol-lowering and IBS probiotics

May 21
11:06 2012
  •  The Spanish biotech company looks for pharma or food companies interested in selling these IP-protected and clinically tested nutraceuticals, AB-LIFE and I3.1, in Europe and around the world

Barcelona (Spain).- The Spanish biotech company AB-Biotics presents these days at Vitafoods Europe, in Geneva, its  new probiotics AB-LIFE and I3.1, focused on the prevention and treatment of cholesterol and irritable bowel syndrome, respectively. The company wants to contact pharma or food companies interested in licensing these functional ingredients in the European. market and / or worldwide.

This important meeting is held in Geneva from 22th to 24th May. AB-Biotics wants to take advantage of this international showcase to look for licensors for two revolutionary probiotics. “The applications of AB-LIFE and I3.1 for the industry are very diverse, so in recent months several companies from different countries have already expressed interest in a possible license agreement”, said Sergi Audivert and Miguel Angel Bonachera, CEOs of AB-Biotics.

 

AB-LIFE: the first probiotic therapy in preventing cardiovascular disease

AB-BIOTICS is looking for pharmaceutical companies interested in licensing AB-LIFE in new markets. AB-LIFE is a nutritional ingredient which reduces cholesterol levels by 14%, according to clinical studies performed by Hospital Puerta del Hierro inMadrid. In addition to its greater efficacy, this new ingredient has another important difference in comparison with other solutions in the market: it not only reduces the levels of cholesterol ingested in the diet, but also blood cholesterol levels, leading to increased effectiveness in a larger number of people. 

With AB-LIFE, the Spanish company AB-BIOTICS has opened the door to probiotic therapy in preventing cardiovascular disease. As well as its possible use in the form of capsules, AB-LIFE can be added to foods with no thermal treatment, such as dairy products, or to drinks or juices using encapsulation techniques. AB-Biotics has already signed agreement agreements with different companies to distribute AB-LIFE in Southeast Europe, particularly in the markets of Slovenia, Croatia, Bosnia-Herzegovina, Serbia, Montenegro, Macedonia and Albania; and also Spain and Brazil.

 

I3.1: a better quality of life for IBS patients

Irritable Bowel Syndrome (IBS) is considered to be the most common gastrointestinal disorder. Its prevalence in western world is estimated to be 10-15% of the adult population. Current treatments for IBS have limited efficacy and severe side effects have been reported in recently approved drugs. AB-BIOTICS has developed I3.1, the first probiotic formula which produces a global improvement of quality of life in IBS patients.

I3.1 consists of a combination of three lactic acid bacteria, more precisely two Lactobacilli and one Pediococcus. Strains in I3.1 formula are able to produce high amounts of short chain fatty acids, especially, butyric acid. SCFAs are readily absorbed by intestinal mucosa and are known to stimulate serotonin release, which modulates both gut motility and sensation. Therefore, in situ production of SCFAs by strains of the I3.1 formula is useful to modulate gut motility and reduce visceral pain. Moreover, I.31 has displayed significant anti-inflammatory activity in two different animal models of gut inflammation, reducing both external symptoms of IBS and molecular markers. Also, 3.1 displays a significant inhibitory activity against many pathogenic bacterial strains, while allowing the growth of common commensal bacteria of the human gastrointestinal flora. Clinical trial has confirmed that I3.1 makes a positive improvement in health-related quality of life of IBS patients, reducing gastrointestinal discomfort and pain. “AB-BIOTICS is looking for pharmaceutical companies interested in licensing I3.1 in different markets –said Sergi Audivert and Miquel Àngel Bonachera, CEOs of AB-BIOTICS-. The product can be dosed both in capsules, tablets and sachets, with a product stability of at least 2 years”.

 

About AB-BIOTICS

AB-BIOTICS is a Spanish biotechnology company focused on research, development, protection and distribution of its own exclusive biotechnological solutions.  The company’s mission is to improve the health and wellbeing of people. The company has an innovative philosophy and its own know-how that allows it to develop avant-garde products with high added value for the market.

 Since 2010, ABBIOTICS is listed in the Alternative Investment Market (MAB, in Spanish). The company has just started its international expansion plan, in order to reinforce their commercial activity and be present in high-potential countries like theUnited States, theUnited Kingdom,Germany,France,Turkey,Mexico andBrazil.

 

More information: http://www.ab-biotics.com/
Nuria Peláez – Communications officer
pelaez@ab-biotics.com
0034 654 352 541

About Author

colin

colin

Related Articles

Food & Drink Business Conference & Exhibition 2016

Upcoming Events

  • September 11, 2019Packaging Innovations & Luxury Packaging London 2019
  • October 1, 2019PPMA Total Show
  • October 17, 2019Future Food-Tech
  • November 18, 2019Plastics Caps and Closures Conference 2019
AEC v1.0.4

find food jobs

The Magazine

F&D Business Preferred Suppliers

New Subscriber

Subscribe Here



Advertisements